Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib

NCT04676334 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT04676334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
Lead sponsor
pharmaand GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2021
Completion date
March 8, 2023
Enrollment
34 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, metastatic castration-resistant prostate cancer, other solid tumor, ovarian cancer, peritoneal cancer